To evaluate the prognostic value of platelet counts in acute kidney injury patients requiring renal replacement therapy.
METHODSThis prospective cohort study was performed in three tertiary-care hospitals. Platelet counts were obtained upon admission to the intensive care unit and during the first week of renal replacement therapy on days 1, 3, 5 and 7. The outcome of interest was the hospital mortality rate. With the aim of minimizing individual variation, we analyzed the relative platelet counts on days 3, 5, 7 and at the point of the largest variation during the first week of renal replacement therapy. Logistic regression analysis was used to test the prognostic value of the platelet counts.
RESULTSThe study included 274 patients. The hospital mortality rate was 62%. The survivors had significantly higher platelet counts upon admission to the intensive care unit compared to the non-survivors [175.5×103/mm3 (108.5–259×103/mm3) vs. 148×103/mm3 (80−141×103/mm3)] and during the first week of renal replacement therapy. The relative platelet count reductions were significantly associated with a higher hospital mortality rate compared with the platelet count increases (70% vs. 44% at the nadir, respectively). A relative platelet count reduction >60% was significantly associated with a worse outcome (mortality rate = 82.6%). Relative platelet count variations and the percentage of reduction were independent risk factors of hospital mortality during the first week of renal replacement therapy.
CONCLUSIONPlatelet counts upon admission to the intensive care unit and at the beginning of renal replacement therapy as well as sequential platelet count evaluation have prognostic value in acute kidney injury patients requiring renal replacement therapy.
Acute kidney injury (AKI) is a frequent complication in patients admitted to the intensive care unit (ICU) and is associated with high mortality rates, particularly when renal replacement therapy (RRT) is required (1). In this setting, the outcomes for AKI patients are mainly related to individual characteristics, such as older age, the number of organs in failure, the presence of co-morbidities, reduced functional capacity and the severity of their acute illness (1–4).
Recently, low platelet counts (PCs) have been recognized as a prognostic marker in the ICU (5,6). Significantly low initial thrombocytopenia (PC<50×103/mm3) has been shown to predict higher mortality rates in community-acquired pneumonia as well as in surgical and medical ICU patients (7–9). Moreover, sequential PC evaluations have been identified as an independent mortality risk factor (10).
In advanced renal failure with uremia, the PC is usually normal or slightly reduced (11). Although 16% to 55% of end-stage renal disease patients may present with thrombocytopenia, values under 100×103/mm3 are infrequent without a superimposed cause (12,13). In AKI, however, a low PC has been recognized as a prognostic marker (6,14). Moreover, severe thrombocytopenia at the beginning of RRT has been associated with hospital mortality (14).
PC measurements are simple, low-cost, usually obtained daily and associated with ICU and hospital mortality rates. However, the prognostic value of the PC and an assessment of its over-time variations in patients requiring RRT in the ICU have not been completely elucidated. Therefore, the aim of the present study was to evaluate the prognostic value of the PC and its sequential evaluation in AKI patients during the first week of RRT.
PATIENTS AND METHODSThis prospective cohort study was conducted from January 2007 to December 2009 in nine medical and surgical ICUs at three tertiary-care hospitals in Rio de Janeiro, Brazil. The study was approved by the ethics committees of the participating institutions without the need for informed consent because this was an observational study.
Patients' characteristicsAll of the AKI patients who needed RRT during the first week of ICU admission were included. End-stage renal disease patients on chronic dialysis and patients within <24 h of admission to the ICU were excluded. AKI was classified according the Risk, Injury, Failure, Loss and End-stage renal disease (RIFLE) criteria immediately before the start of RRT. Decisions to start, change the method of, and stop RRT were made together by the nephrologists and intensivists individually responsible for the patients. The same team of nephrologists managed the patients in all of the participating ICUs. The prescribed RRT modalities were daily conventional dialysis (daily-IHD), prolonged intermittent RRT (PIRRT) and continuous RRT (CRRT) according to the patient's hemodynamic status (R.I.O.S. allocation system) (4). CRRT was employed in patients receiving vasoactive drugs and in patients with the potential for hemodynamic and neurologic instabilities. The RRT procedures were performed using DIAPACT (B. Braun, Melsungen, Germany), and the intermittent procedures were performed using AK200 series (Gambro, Lund, Sweden) machines. Polysulfone (PS, Fresenius, Frankfurt, Germany) membranes, customized bicarbonate solutions and a blood flow rate of 200 to 300 ml/min were prescribed in each dialysis procedure. When anticoagulation was needed, low molecular weight (LMW) heparin was prescribed. Demographic, clinical and laboratory data were prospectively collected. The previous comorbidities [Charlson index and chronic health status (Knaus)] (15,16), main diagnosis for ICU admission, pre-morbid renal function, need for mechanical ventilation or vasopressors for more than 24 h, contributing factors for AKI and severity of the acute illness [SAPS II (17) and SOFA (18)] were also recorded.
Platelet Counts DataPCs were determined daily using a Sysmex XE210D. Thrombocytopenia was considered present when the PC was <150×103/mm3 (8). A 10% range variation in PC was established as acceptable for determining a stable measurement. The prospectively collected PC data included the following items: absolute PC on the day of ICU admission (D0) and absolute PC during the first week of RRT on days 1, 3, 5 and 7 (D1, D3, D5 and D7, respectively).
The relative PC variation during the first week of RRT was calculated as follows: relative PC between D1-D3 of RRT = [(PC D3-PC D1/PC D1)]∗100; relative PC between D1-D5 of RRT = [(PC D5- PC D1/PC D1)]∗100; relative PC between D1-D7 of RRT = [(PC D7-PC D1/PC D1)]∗100; relative PC at the point of highest PC variation (nadir or acme) = [(PC D3-PCD1 or PC D5-PCD1 or PC D7-PC D1)/PC D1]∗100, according to an individual's variation time points.
The measured PCs were stratified as follows (10). The absolute PCs on the first day of RRT were divided into ≥150×103/mm3, 100−149.9×103/mm3, 50−99.9×103/mm3 and <50×103/mm3. The relative PC variations were classified as reduced, stable or increased over the D1-D3, D1-D5 and D1-D7 assessment periods. The relative PC reductions during the first week of RRT were divided into ≥60%, 30% to 59.9%, 10% to 29.9% and <10% over the D1-D3, D1-D5 and D1-D7 assessment periods. The relative PC reductions during the first week of RRT using the PC nadir were divided into ≥60%, 30% to 59.9%, 10% to 29.9% or ≤10% over the D1-D3; D1-D5 or D1-D7 assessment periods. The hospital mortality rate was the outcome of interest.
Statistical analysisA single data manager entered the data into a computer database. Standard descriptive statistics were used to describe the study population. Continuous variables are presented as the mean±SD or median (25–75% interquartile range) and were compared using Student's t-test or the chi-squared test, as appropriate. Logistic regression analysis was used to identify the factors associated with the hospital mortality rate. Variables yielding p-values <0.25 by the univariate analysis and variables considered clinically important were entered in a forward multivariate logistic regression analysis. The results of both the uni- and multivariate analyses were summarized by estimating the odds ratios (ORs) and their respective 95% confidence intervals (CIs). Possible interactions and collinear relationships were tested. Discrimination was evaluated by calculating the area under the receiver operating characteristic curve (AROC) (19). The Hosmer-Lemeshow goodness-of-fit test was used to evaluate the model's calibration (22). A two-tailed p<0.05 was considered statistically significant.
RESULTSCharacteristics of the study populationA total of 274 patients who developed AKI requiring RRT during the first week of ICU admission were included in the study. The mean age was 69±16 years. The main cause of AKI was sepsis (68%). At the time that dialysis was indicated, the severity of the renal injury was classified using the RIFLE criteria as follows: RIFLE-F = 143 (52.2%); RIFLE-I = 59 (21.5%), and RIFLE-R = 72 (26.3%). The indications for RRT (the same patient could have more than one simultaneously) were as follows: hypervolemia [150 (55%)], metabolic acidosis [168 (61%)], hyperkalemia [24 (9%)], dysnatremias [14 (5%)], azotemia [128 (47%)] and oligoanuria [59 (22%)]. CRRT was the most common dialysis modality, and it was prescribed in 220 patients (80.2%) with hemodynamic or neurologic instability or severe metabolic disorders. Anticoagulation was not prescribed for most RRT procedures [244 patients (89%)]. LMW heparin was used in all 30 patients (11%) who received anticoagulation on at least one occasion. The patients' main demographic and clinical characteristics and the laboratory results are shown in Table 1.
Patient demographics, clinical characteristics and laboratory data (n = 274).a)
| Variables | AKI (n = 274) |
|---|---|
| Age (years) | 69±16 |
| Male gender | 153 (55.8%) |
| Poor chronic health status (Knaus C or D) | 99 (36.1%) |
| Charlson Co-morbidity Index (points) | 3 (1–5) |
| Charlson Co-morbidity Index ≥1 point | 230 (84%) |
| SAPS II (ICU admission, points) | 46 (39–54) |
| SAPS II (ICU admission, probability of death, %) | 36.9 (23–55) |
| SOFA on day 1 of RRT | 8±3.1 |
| SOFA on day 1 of RRT (except for renal and hematologic points) | 6±3.1 |
| APACHE II (ICU admission, points) | 21 ± 6 |
| RIFLE at RRT decision | |
| Risk | 72 (26%) |
| Injury | 59 (21%) |
| Failure | 143 (52%) |
| Clinical admission | 221 (81%) |
| Sepsis | 186 (68%) |
| Mechanical ventilation | 198 (72%) |
| Vasopressors | 189 (69%) |
| Platelet counts | |
| Platelet counts on ICU admission (x103/mm3) | 150 (94–253) |
| <150×103/mm3 on first day of ICU [n (%)] | 137 (50%) |
| <150×103/mm3 on first day of RRT [n (%)] | 131 (48%) |
| <150×103/mm3 on at least one measurement [n (%)] | 192 (70%) |
| Length of ICU stay (days) | 14 (8–31) |
| Length of hospital stay (days) | 22 (11–44) |
| Decision to withhold/withdraw treatment | 36 (13.1%) |
| ICU mortality rate | 160 (58.4%) |
| Hospital mortality rate | 170 (62%) |
The results are expressed as the mean±standard deviation or median (interquartile range); n = number of patients (%); RRT = renal replacement therapy; ICU = intensive care unit; RIFLE = Risk, Injury, Failure, Loss and End-Stage Renal Disease acute kidney injury severity score; SOFA = sepsis-related organ failure assessment; SAPS II = Simplified Acute Physiology Score.
The ICU and hospital mortality rates were 58.4% and 62%, respectively. The mean ICU and in-hospital lengths of stay were 14 days (range 8–31 days) and 22 days (range 11–44 days), respectively. In the univariate analysis, mechanical ventilation, vasoactive drugs, poor chronic health status (Knaus C and D) and co-morbidities (Charlson>1) were significantly associated with a worse outcome (Table 2).
Univariate analysis of patient characteristics associated with hospital mortality rate (n = 274).a)
| Variables | Survivors n = 104 (38%) | Non-Survivors n = 170 (62%) | Odds Ratio (95% CI) | p-value |
|---|---|---|---|---|
| Age (years) | 63.4±17.5 | 72.8±14.2 | 1.04 (1.02–1.06) | <0.001 |
| Male gender | 54 (51.9%) | 99 (58.3%) | 1.2 (0.7–2.1) | 0.30 |
| Clinic admission | 82 (78.9%) | 139 (81.8%) | 1.2 (0.6–2.2) | 0.50 |
| Sepsis | 64 (61.5%) | 122 (70.6%) | 1.5 (0.9–2.6) | 0.70 |
| Mechanical ventilation | 68 (65.5%) | 130 (76.5%) | 1.7 (1.0–2.9) | 0.04 |
| Vasoactive drugs | 61 (58.7%) | 128 (98.5%) | 2.1 (1.2–3.6) | 0.04 |
| Poor chronic health status (Knaus C and D) | 14 (13.5%) | 85 (50.0%) | 6.4 (3.9–12.7) | 0.001 |
| Co-morbidities (Charlson >1) | 77 (74.0%) | 153 (90.0%) | 3.1 (1.6–6.1) | 0.001 |
| SAPS II (on first day of RRT) | 41.6±10.7 | 49.9±10.6 | 1.08 (1.05–1.11) | <0.001 |
| SOFA (without renal and hematologic points) | 3.8±3.0 | 5.4±3.0 | 2.6 (1.8–3.7) | <0.001 |
| Dialysis on the first day of ICU admission | 82 (78.9%) | 113 (66.5%) | 0.5 (0.3–0.9) | 0.02 |
On D0 of the ICU admission, survivors had a significantly higher mean PC than non-survivors [175.5×103/mm3 (108.5−259×103/mm3) vs. 148×103/mm3 (80−141×103/mm3)] (p = 0.03). On D1 of RRT, 8.8% of patients already had severe thrombocytopenia (PC <50×103/mm3). The hospital mortality in this group was significantly higher (87.5%, p = 0.014). During the first week of RRT, the survivors had a significantly higher mean PC than the non-survivors [D1 of RRT = 178×103/mm3 (113.5−258×103/mm3) vs. 148.5×103/mm3 (83−241×103/mm3) (p = 0.02); D3 of RRT = 137×103/mm3 (82−211×103/mm3) vs. 97.5×103/mm3 (52−178×103/mm3) (p = 0.001); D5 of RRT = 129×103/mm3 (69.5−218×103/mm3) vs. 79×103/mm3 (41.3−139.5×103/mm3) (p = 0.001); D7 of RRT = 156×103/mm3 (95.9−238×103/mm3) vs. 88.5×103/mm3 (46−166×103/mm3) (p = 0.001)] (Figure 1).
To remove baseline individual PC variations during the first week of RRT, relative PCs and relative PCs using the observed main variation point (nadir or acme) were calculated and analyzed. Reduced or stabilized relative PCs were associated with a higher mortality rate (Table 3). Similarly, a higher percentage of the relative PC reduction during the first week of RRT was associated with a higher hospital mortality rate. A PC reduction >60% was associated with a worse outcome on D1-D3 (70.3%, p = 0.42), D1-D5 (72.5%, p<0.001), D1-D7 (78.0%, p<0.001) and at the nadir (82.5%, p<0.001). The results are shown in Table 3. Figure 2 shows the Kaplan–Meier survival curve using the percentage of relative PC reduction at the nadir.
Hospital mortality rate according to platelet count variations and reductions.
| Stratification of relative platelet counts | D1-D3 (n = 274) | D1-D5 (n = 248) | D1-D7 (n = 209) | Largest relative platelet count variation∗(n = 274) | ||||
|---|---|---|---|---|---|---|---|---|
| Patients n (%) | Mortality rate (%) | Patients n (%) | Mortality rate (%) | Patients n (%) | Mortality rate (%) | Patients n (%) | Mortality rate (%) | |
| Variation ‡ | ||||||||
| Reduction <10% | 168 (61.3) | 65.5 | 180 (72.6) | 67.8 | 128 (61.3) | 64.1 | 135 (49.3) | 70.4 |
| Stable | 60 (21.9) | 63.3 | 31 (12.5) | 41.9 | 27 (12.9) | 59.3 | 59 (21.5) | 67.8 |
| Increase >10% | 46 (16.8) | 47.8 | 37 (14.9) | 32.4 | 54 (25.8) | 29.6 | 80 (29.2) | 43.8 |
| P-value | p = 0.089 | p<0.001 | p<0.001 | p<0.001 | ||||
| Reduction‡‡ | Relative platelet count nadir∗∗(n = 274) | |||||||
| ≥60% | 37 (13.5) | 70.3 | 51 (20.6) | 72.5 | 41 (19.6) | 78.0 | 23 (8.4) | 82.6 |
| 30–59.9% | 75 (27.4) | 62.7 | 81 (32.7) | 65.4 | 56 (57.1) | 57.1 | 53 (19.3) | 69.8 |
| 10–29.9% | 56 (20.4) | 66.1 | 48 (19.4) | 66.7 | 31 (14.8) | 58.1 | 59 (21.5) | 66.1 |
| <10% | 106 (38.7) | 56.6 | 68 (36.8) | 36.8 | 81 (38.8) | 39.5 | 139 (50.7) | 54.0 |
| P-value | p = 0.42 | p<0.001 | p<0.001 | p<0.001 | ||||
PC = platelet count; RRT = renal replacement therapy; Days (D) 1,3,5,7 of RRT; ‡ = Relative PC variation = PC (D3-D1)/D1×100; PC (D5-D1)/D1×100; PC (D7-D1)/D1] ×100 (results are shown as reduction> 10%, stable and increase >10% compared to D1); ∗ = largest relative PC variation = relative PC (nadir or acme at D1-D3 or D1-D5 or D1-D7); ‡‡ = Relative PC reduction = PC (D3-D1)/D1×100; PC (D5-D1)/D1×100; PC (D7-D1)/D1] ×100 (results are shown as percentages); ∗∗ = Nadir = Relative PC reduction at the point of the largest relative PC reduction at D1-D3 or D1-D5 or D1-D7.
Kaplan-Meier curve of survival outcomes following hospital admissions of acute kidney injury patients in the intensive care setting according to percentage of relative platelet count (PC) at the nadir during the first week of renal replacement therapy (RRT). A PC reduction >60% was associated with worse outcomes (p<0.001).
To evaluate the prognostic value of PCs in the study population, two different models were built and entered into the multivariate analysis. To avoid collinearity, each model included a severity of illness score (SOFA) without renal and hematologic points and a platelet variable (either the reduction or stabilization of the relative PC or the percentage of relative PC reduction) (Table 4).
Multivariate models of the predictive factors for hospital mortality in acute kidney injury patients requiring renal replacement therapy (n = 274).
| Model 1 including relative PC variation | Odds Ratio (95% CI) | p-value |
|---|---|---|
| PC on D1 of RRT∗ | ||
| 100×103−149.9/mm3 | 1.5 (0.7–3.3) | 0.27 |
| 50×103− 99.9/mm3 | 2.39 (0.97–5.5) | 0.057 |
| <50×103/mm3 | 13.3 (2.6–65.8) | 0.002 |
| Co-morbidities (Charlson >1) | 3.3 (1.4–7.7) | 0.006 |
| Poor chronic health status (Knaus C and D) | 5.28 (2.60–10.69) | 0.0001 |
| Dialysis on the first day of ICU admission | 0.43 (0.21–0.87) | 0.02 |
| SOFA without renal and hematologic points | 1.05 (1.02–1.09) | 0.0001 |
| Relative PC variation | ||
| Stabilization | 3.2 (1.36–7.92) | 0.008 |
| Reduction >10% | 4.02(1.85–8.73) | 0.001 |
| Constant | ||
| AUROC = 0.84; (95% CI, 0.79–0.88); | ||
| Goodness-of-fit test, (χ2 = 6.215, p = 0.623) | ||
| Model 2 including relative PC reduction | ||
| PC on D1 of RRT∗ | ||
| 100×103−149.9/mm3 | 1.5 (0.7–3.3) | 0.26 |
| 50×103−99.9/mm3 | 2.0 (0.9–4.7) | 0.087 |
| <50×103/mm3 | 8.3 (1.8–38.3) | 0.006 |
| Co-morbidities (Charlson >1) | 3.1 (1.3–7.3) | 0.009 |
| Poor chronic health status (Knaus C and D) | 5.5 (2.7–11.1) | 0.0001 |
| Dialysis on the first day of ICU admission | 0.4 (0.21–0.87) | 0.019 |
| SOFA without renal and hematologic points | 1.0 (1.03–1.09) | 0.0001 |
| Relative PC reduction (%)∗∗ | ||
| ≥10–29.9% | 1.6 (0.7–3.5) | 0.194 |
| ≥30–59.9% | 2.2 (0.9–5.2) | 0.062 |
| ≥60% | 4.9 (1.3–17.6) | 0.014 |
| Constant | ||
| AUROC = 0.83; CI (95%) (0.78–0.88); | ||
| Goodness-of-fit test, (χ2 = 6.731, p = 0.566) |
AKI = acute kidney injury; RRT = renal replacement therapy; ICU = intensive care unit; PC = platelet count; OR = odds ratio; CI = confidence interval; AROC = area under the receiver operating characteristic curve; ∗PC on D1 of RRT = platelet count on the first day of renal replacement therapy, ∗∗ Relative PC reduction at the point of the largest variation = [(PC at largest variation point (D3, D5 or D7)-PC on D1/PC on D1)] x100; SOFA = Sepsis-related Organ Failure Assessment.
In this prospective study, we demonstrated that thrombocytopenia was significantly associated with a worse outcome in dialytic AKI in the ICU and that sequential PC analysis could be used as a prognostic tool in this population.
Thrombocytopenia is one of the most common laboratory findings in the ICU (5,21–22). In the present study, 50% of patients already had PCs below 150×103/mm3 upon ICU admission. Moreover, 48% of patients had thrombocytopenia on the first day of RRT, and 70% had at least one PC measurement below 150×103/mm3 during the study. Nonetheless, a PC <50×103/mm3 was observed in only 24 patients (8.8%) upon RRT initiation and in 40 patients (14%) throughout the first week of RRT. Our data suggest that, similar to the findings that have been described for the general ICU population, in AKI patients requiring RRT, thrombocytopenia occurs frequently, but severe thrombocytopenia is unusual (23,24).
Lower PCs have been associated with higher ICU mortality rates. Brogly et al. (7) reported that a PC of <50×103/mm3 on the first day in the ICU in patients with severe community-acquired pneumonia was an independent factor for hospital mortality. Similarly, Vandershueren et al. (8) reported that thrombocytopenia occurring during ICU admission was an independent marker of illness severity and was associated with a higher hospital mortality rate. In AKI patients, thrombocytopenia on the first day of RRT has been associated with a worse outcome (14). Similarly, in the present study, severe thrombocytopenia (a PC <50×103/m m3) on D1 of RRT was associated with a significantly higher in-hospital mortality rate compared with the whole study population (87.5% vs. 62%).
In healthy individuals, the consistency and reproducibility of PCs are well established (25,26). The normal baseline PC range is 150 to 350×103/mm3 for the general population, and the amount of variation for a given individual on sequential evaluations is small (approximately 60×103/mm3) (23). However, in the ICU setting, the PC variation over time behaves as a more sensitive variable than the absolute PC to distinguish survivors and non-survivors (27). To minimize the basal individual PC differences, we sequentially analyzed the relative PCs and showed that a reduced relative PC during the first week of RRT was associated with a higher mortality. Nevertheless, this result was only statistically significant after D5 of RRT. Moreau et al. (10) recently described the profile of PCs in ICU patients. The authors noted that the drop in PCs from the normal range occurred during the first three days in the ICU, and the nadir was observed on D3 in the survivors and D4 in the non-survivors. This result may have been a confounding factor in our results. However, when we minimized this possible individual PC variation over time, performing the analysis based on the point of largest PC variation (nadir or acme), the relative PC reduction or stabilization was significantly associated with a higher hospital mortality rate. Similarly, a higher relative PC reduction was associated with a worse outcome, particularly when the reduction was over 60%. Our results corroborate the results observed in the literature for general ICU patients (10).
In the present study, the patients who presented a bimodal PC pattern with an increase in PC after developing thrombocytopenia had a more favorable prognosis. Our data corroborated the reports of Akca et al. (24) and Nijsten et al. (27) who identified the same bimodal PC pattern more frequently in critically ill survivors than in non-survivors.
The sequential evaluation of PCs in the present study, similarly to the findings for ICU patients but different from the results observed for end-stage renal disease patients, indicate that PC variation is an independent predictor of the hospital mortality rate in patients with AKI requiring RRT in the ICU and performs better than many prognostic markers in AKI (7–13,28). However, we would reiterate that no prognostic score should be used for predictions about individual patients, although using a simple and accessible measurement such as PC may help in clinical decision making to improve resource allocation in the ICU and in stratifying AKI patients in need of RRT in clinical trials.
As for the limitations of our analysis, we did not measure PCs in the dialysis circuit nor did we routinely quantify the heparin-induced antibodies. Previous reports have shown that small continuous platelet losses make a cumulative contribution to the thrombocytopenia observed in dialyzed AKI patients in the ICU (29). However, these losses seem to be related to the in vivo use of cuprophane membranes and to the non-albumin content of dialysis solutions when tested in artificial systems (29). Despite the negative correlation between the blood flow rate and platelet loss in CRRT, Docci et al. reported that platelet losses in RRT can be minimized by increasing the blood flow rate and that such losses can be avoided almost entirely when the blood flow rate is maintained >200 ml/min during a dialysis procedure (30,31). In the present study, all of the patients underwent RRT, and PS membranes were prescribed for all of the procedures. In addition, we maintained a 200-ml/min blood flow rate even during CRRT. LMW heparin was prescribed in 11% of cases, and no heparin-induced thrombocytopenia was suspected or confirmed.
In conclusion, the PCs upon ICU admission and at the beginning of RRT as well as its sequential evaluation during the first week of RRT have prognostic value in AKI patients requiring RRT.
AUTHOR CONTRIBUTIONSValente C collected the data and prepared the manuscript. Soares M and Cardoso L performed the statistical analysis and revised the manuscript. Rocha E revised the manuscript. Maccariello E performed the data analysis and wrote the manuscript.
In addition to institutional funds, Dr. Soares received an individual research grant from CNPq.
No potential conflict of interest was reported.